Literature DB >> 17928528

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

Pablo G Longo1, Luca Laurenti, Stefania Gobessi, Simona Sica, Giuseppe Leone, Dimitar G Efremov.   

Abstract

Sustained engagement of the B-cell receptor (BCR) increases apoptosis resistance in chronic lymphocytic leukemia (CLL) B cells, whereas transient stimulation usually has an opposite effect. The antiapoptotic BCR signal has been associated with prolonged activation of the PI3K/Akt and MEK/ERK pathways, which are key regulators of survival and proliferation in various cell types. To further define the relative contribution of the Akt and ERK kinases in regulating CLL B-cell survival, we introduced constitutively active mutants of Akt and MEK in primary CLL B cells and evaluated changes in the expression of relevant pro- and antiapoptotic proteins. Sustained activation of Akt resulted in increased leukemic cell viability and increased expression of the antiapoptotic proteins Mcl-1, Bcl-xL, and X-linked inhibitor of apoptosis protein (XIAP), thus largely recapitulating the effects of sustained BCR stimulation. Constitutively active MEK2 also up-regulated XIAP, but did not show a significant impact on leukemic cell survival. Down-regulation of Mcl-1 by siRNA treatment induced rapid and potent apoptosis in CLL B cells and blocked the antiapoptotic effect of sustained BCR stimulation, whereas down-regulation of Bcl-xL and XIAP did not affect leukemic cell viability. These data demonstrate that Akt and Mcl-1 are major components of a survival pathway that can be activated in CLL B cells by antigen stimulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928528     DOI: 10.1182/blood-2007-05-089037

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  120 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

2.  A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes.

Authors:  Brian A McCarthy; Sophia Yancopoulos; Mike Tipping; Xiao-Jie Yan; Xue Ping Wang; Fiona Bennett; Wentian Li; Martin Lesser; Santanu Paul; Erin Boyle; Carolina Moreno; Rosa Catera; Bradley T Messmer; Giovanna Cutrona; Manlio Ferrarini; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Andrew C Rawstron; Nicholas Chiorazzi
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

Review 3.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

4.  Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.

Authors:  Jeremy T Larsen; Tait D Shanafelt; Jose F Leis; Betsy LaPlant; Tim Call; Adam Pettinger; Curtis Hanson; Charles Erlichman; Thomas Matthew Habermann; Craig Reeder; Daniel Nikcevich; Deborah Bowen; Michael Conte; Justin Boysen; Charla Secreto; Connie Lesnick; Renee Tschumper; Diane Jelinek; Neil E Kay; Wei Ding
Journal:  Am J Hematol       Date:  2017-06-01       Impact factor: 10.047

5.  Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.

Authors:  Rong Chen; Lei Guo; Yuling Chen; Yingjun Jiang; William G Wierda; William Plunkett
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

Review 6.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

7.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

8.  Cadmium promotes the proliferation of triple-negative breast cancer cells through EGFR-mediated cell cycle regulation.

Authors:  Zhengxi Wei; Xiulong Song; Zahir A Shaikh
Journal:  Toxicol Appl Pharmacol       Date:  2015-09-15       Impact factor: 4.219

9.  The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Authors:  Matthew D Blunt; Stefan Koehrer; Rachel C Dobson; Marta Larrayoz; Sarah Wilmore; Alice Hayman; Jack Parnell; Lindsay D Smith; Andrew Davies; Peter W M Johnson; Pamela B Conley; Anjali Pandey; Jonathan C Strefford; Freda K Stevenson; Graham Packham; Francesco Forconi; Greg P Coffey; Jan A Burger; Andrew J Steele
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

10.  High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Nicole Weit; Nils Lilienthal; Michael Hallek; Michael J Keating; Dan Jones
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.